Skip to main content

Table 1 Demographics and pre-existing comorbidities in non-transplant and transplant patients with NDMM by LOT

From: Frontline treatment patterns and attrition rates by subsequent lines of therapy in patients with newly diagnosed multiple myeloma

 

Non-transplant

Transplant

Characteristic

Non-transplant overall

N = 22,062

By use of LOT

 

Transplant overall

N = 2763

By use of LOT

 

Frontline induction therapy

Frontline induction therapy by use of consolidation therapya

Frontline induction therapy

> 1 LOT

n = 9505

Only 1 LOT

n = 12,557

P-valueb

> 1 LOT

n = 2184

Only 1 LOT

n = 579

P-valueb

Yes

n = 1682

Yes

n = 187

No

n = 1495

No

n = 1081

Age at MM diagnosis, years

 Mean (SD)

71.1 (10.4)

70.4 (10.1)

71.6 (10.6)

< 0.0001

62.3 (8.7)

62.3 (8.6)

62.4 (9.0)

0.6397

62.9 (8.6)

61.0 (9.1)

63.1 (8.5)

61.4 (8.8)

 Median (Q1–Q3)

72.0 (65.0–79.0)

72.0 (65.0–78.0)

73.0 (65.0–80.0)

< 0.0001

65.0 (57.0–69.0)

64.0 (57.0–69.0)

65.0 (57.0–69.0)

0.3294

65.0 (58.0–69.0)

62.0 (55.0–68.0)

65.0 (58.0–69.0)

63.0 (56.0–68.0)

 Min, max

20, 100

23, 95

20, 100

 

27, 82

27, 82

31, 80

 

27, 82

37, 80

27, 82

28, 80

Age categories, n (%)

   

< 0.0001

   

0.7143

    

 < 65

5197 (23.6)

2304 (24.2)

2893 (23.0)

 

1378 (49.9)

1094 (50.1)

284 (49.1)

 

781 (46.4)

NR

NR

597 (55.2)

 65–74

7741 (35.1)

3581 (37.7)

4160 (33.1)

 

1298 (47.0)

1019 (46.7)

279 (48.2)

 

840 (49.9)

74 (40)

766 (51)

458 (42.4)

 75–84

7536 (34.2)

3174 (33.4)

4362 (34.7)

 

87 (3.1)

71 (3.3)

16 (2.8)

 

61 (3.6)

NR

NR

26 (2,4)

 ≥ 85

1588 (7.2)

446 (4.7)

1142 (9.1)

 

–

–

–

 

–

–

–

–

Male, n (%)

11,097 (50.3)

4731 (49.8)

6366 (50.7)

0.1745

1556 (56.3)

1249 (57.2)

307 (53.0)

0.0723

927 (55.1)

110 (59)

817 (55)

629 (58.2)

Race, n (%)c

   

< 0.0001

   

< 0.0001

    

 White

13,176 (59.7)

5847 (61.5)

7329 (58.4)

 

1263 (45.7)

1069 (48.9)

194 (33.5)

 

709 (42.2)

130 (70)

579 (39)

554 (51.2)

 Black

2901 (13.1)

1269 (13.4)

1632 (13.0)

 

252 (9.1)

203 (9.3)

49 (8.5)

 

128 (7.6)

25 (13)

103 (7)

124 (11.5)

 Asian

428 (1.9)

205 (2.2)

223 (1.8)

 

26 (0.9)

NR

NR

 

NR

NR

NR

NR

 Hispanic

225 (1.0)

108 (1.1)

117 (0.9)

 

NR

NR

NR

 

NR

NR

NR

NR

 Unknown/other

5332 (24.2)

2076 (21.8)

3256 (25.9)

 

1207 (43.7)

880 (40.3)

327 (56.5)

 

821 (48.8)

29 (16)

792 (53)

386 (35.7)

Charlson Comorbidity Index

 Mean (SD)

1.5 (1.8)

1.4 (1.7)

1.5 (1.8)

0.0065

1.2 (1.5)

1.1 (1.4)

1.3 (1.7)

0.0306

1.2 (1.5)

0.8 (1.5)

1.3 (1.5)

1.1 (1.4)

 Median (Q1–Q3)

1.0 (0–2.0)

1.0 (0–2.0)

1.0 (0–2.0)

0.5335

1.0 (0–2.0)

1.0 (0–2.0)

1.0 (0–2.0)

0.2183

1.0 (0–2.0)

0.0 (0–1.0)

1.0 (0–2.0)

0.0 (0–2.0)

 Min, max

0, 13

0, 12

0, 13

 

0, 11

0, 10

0, 11

 

0, 11

0, 8

0, 11

0, 10

Comorbidities during 180 days prior to start of first LOT, n (%)

 Any comorbidity below

14,539 (65.9)

6164 (64.9)

8375 (66.7)

0.0042

1638 (59.3)

1261 (57.7)

377 (65.1)

0.0013

1051 (62.5)

82 (44)

969 (65)

587 (54.3)

 Cardiac arrhythmia

4327 (19.6)

1627 (17.1)

2700 (21.5)

< 0.0001

294 (10.6)

232 (10.6)

62 (10.7)

0.9528

182 (10.8)

16 (9)

166 (11)

112 (10.4)

 Congestive heart failure

2984 (13.5)

1008 (10.6)

1976 (15.7)

< 0.0001

117 (4.2)

95 (4.3)

22 (3.8)

0.5589

63 (3.7)

NR

NR

54 (5.0)

 Hypertension, complicated

3718 (16.9)

1382 (14.5)

2336 (18.6)

< 0.0001

260 (9.4)

177 (8.1)

83 (14.3)

< 0.0001

165 (9.8)

NR

NR

95 (8.8)

 Hypertension, simple

11,698 (53.0)

5059 (53.2)

6639 (52.9)

0.6022

1316 (47.6)

1016 (46.5)

300 (51.8)

0.0234

847 (50.4)

62 (33)

785 (53)

469 (43.4)

 Hepatic disease

972 (4.4)

388 (4.1)

584 (4.7)

0.0415

151 (5.5)

102 (4.7)

49 (8.5)

0.0004

104 (6.2)

NR

NR

47 (4.3)

 Pulmonary circulation disorders

1027 (4.7)

348 (3.7)

679 (5.4)

< 0.0001

56 (2.0)

39 (1.8)

17 (2.9)

0.0807

32 (1.9)

NR

NR

24 (2.2)

 Renal impairment

5317 (24.1)

2083 (21.9)

3234 (25.8)

< 0.0001

471 (17.0)

352 (16.1)

119 (20.6)

0.0116

298 (17.7)

23 (12)

275 (18)

173 (16.0)

 Valvular disease

2258 (10.2)

887 (9.3)

1371 (10.9)

0.0001

158 (5.7)

119 (5.4)

39 (6.7)

0.2357

92 (5.5)

NR

NR

66 (6.1)

  1. LOT Line of therapy, MM Multiple myeloma, NDMM Newly diagnosed multiple myeloma, NR Not reported, Q Quartile, SD Standard deviation
  2. Values of 1–10 have not been reported to conform to the Centers for Medicare and Medicaid Services cell size suppression policy; Similarly, data have not been reported for categorical variables and by subgroup to avoid making it possible to calculate the values of the NR cells
  3. aConsolidation therapy was evaluated among patients with NDMM who received frontline induction therapy, and was required to have been ongoing for ≥1 month after ASCT
  4. bP-value vs. > 1 LOT; P-values were computed using chi-squared tests for categorical variables and t-tests for continuous variables
  5. cRace data were not available in the OPTUM™ Commercial Claims database for patients who received transplant
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us